|
|
|
|
Everolimus Is an Effective Treatment Option for Patients With Pancreatic Neuroendocrine Tumours: Presented at
- Everolimus, administered alone or with octreotide long acting release (LAR), is a safe treatment option for patients with advanced pancreatic neuroendocrine tumours (NET) who have failed chemotherapy, researchers stated on June 25, here at...
|
|
|
Bill to Fund Neuroendocrine Immune Disorder Center of Excellence in New Jersey OKd by Assembly, Now
Research center would be dedicated to ME/CFS, fibromyalgia, Gulf War Illness, Lyme disease, MCS, and other environmental illnesses.Sat., Jun 27, 2009, via the Co-Cure Listserv: Fantastic news! The New Jersey Assembly has unanimously...
|
|
|
June 27, 2009
Research center would be dedicated to ME/CFS, fibromyalgia, Gulf War Illness, Lyme disease, MCS, and other environmental illnesses.Sat., Jun 27, 2009, via the Co-Cure Listserv: Fantastic news! The New Jersey Assembly has unanimously...
|
|
|
Afinitor And Sandostatin LAR Phase II Data Show Advanced Pancreatic NET Patients Remain Progression-Free For N
New data demonstrate that treatment with Afinitor (everolimus) in combination with Sandostatin LAR (octreotide acetate suspension for injection) and Afinitor monotherapy may have the potential to stabilise tumour growth in patients with...
|
|
|
Medical News: The AGA Foundation Awards Grant To Dr. Michael Choi To Further His Research On Carcinoid Tumors
The AGA Foundation for Digestive Health and Nutrition (FDHN) has named Michael Y.Choi , MD, the first recipient of the Mary Terese Hartzheim Award for Neuroendocrine Tumor Research. This new research award was created for young...
|
|
|
The AGA Foundation Awards Grant To Dr. Michael Choi To Further His Research On Carcinoid Tumors
The AGA Foundation for Digestive Health and Nutrition (FDHN) has named Michael Y.Choi , MD, the first recipient of the Mary Terese Hartzheim Award for Neuroendocrine Tumor Research. This new research award was created for young...
|
|
|
Afinitor and Sandostatin LAR Phase II data show advanced pancreatic NET patients remain progression-free for n
- New data demonstrate that treatment with Afinitor (everolimus) Tablets in combination with Sandostatin LAR (octreotide acetate suspension for injection) and Afinitor monotherapy may have the potential to control tumor growth in patients...
|
|
|
Afinitor and Sandostatin LAR Phase II Data Show Advanced Pancreatic NET Patients Remain Progression-Free for N
* 84% of patients with advanced pancreatic neuroendocrine tumors (NET) who took Afinitor combined with Sandostatin LAR experienced tumor shrinkage * Patients with this rare and aggressive form of cancer have limited treatment options...
|
|
|
Reason to smile: BYU men's basketball coach Rose optimistic about cancer battle
BYU basketball head coach Dave Rose smiles as he talks about his battle with cancer over the past few weeks during a press conferenceWednesday in Provo.(Steve Griffin/The Salt Lake Tribune ) Jun 18: Jun 17: Provo One day, BYU basketball...
|
|
|
Afinitor, and Sandostatin, LAR, Phase II data show advanced pancreatic NET patients remain progres
* 84% of patients with advanced pancreatic neuroendocrine tumors (NET) who took Afinitor combined with Sandostatin LAR experienced tumor shrinkage * Patients with this rare and aggressive form of cancer have limited treatment options...
|
|
|
PRESS RELEASE Novartis Afinitor And -3- (DJ)
gastrointestinal_carcinoid_tumors_14.asp?rnav=cri.Accessed May 2009. [6] Gunter K, Perren A, Heitz PU The Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification. of the New York Acad of Sci.
|
|
|
PRESS RELEASE Novartis Afinitor And Sandostatin LAR... (DJ)
Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. =--------------------------------------------------------------------- =------------- * 84% of...
|
|
|
Delcath Systems Granted Third Orphan Drug Designation
Delcath Systems, Inc.(NASDAQ: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the United States Food and Drug Administration ('FDA') granted...
|
|
|
High-Dose Melphalan Granted Orphan Drug Status for Neuroendocrine Liver Metastases
_ High-Dose Melphalan Granted Orphan Drug Status for Neuroendocrine Liver Metastases.
|
|
|
High-Dose Melphalan Granted Orphan Drug Status for Neuroendocrine Liver Metastases
_ High-Dose Melphalan Granted Orphan Drug Status for Neuroendocrine Liver Metastases.
|
|
|
High-Dose Melphalan Granted Orphan Drug Status for Neuroendocrine Liver Metastases
_ High-Dose Melphalan Granted Orphan Drug Status for Neuroendocrine Liver Metastases.
|
|
|
Neuroendocrine basis of social bonding
A University of Michigan study has identified a likely reason: feeling emotionally close to a friend increases levels of the hormone progesterone, helping to boost well-being and reduce anxiety and stress.'This study establishes...
|
